Svantesson H
Department of Rheumatology, University Hospital of Lund, Sweden.
Clin Exp Rheumatol. 1991 Jan-Feb;9 Suppl 6:47-50.
Six children with JCA and one with SLE, aged 11.7 to 17.1 years, have been treated with human growth hormone (hGH) for six months to three years because of growth retardation. Their height SDS score ranged from -2.4 to -6.4. All have been treated with corticosteroids for 8.4 years on average. The doses of prednisolone were low at the start of the hGH therapy (mean 1.25 mg/day or 2.75 mg/alternate day). Daily doses of hGH ranged from 0.07 to 0.2 IU/kg body weight and day. The growth rate increased during the first year in all but one patient. The mean pretreatment growth rate was 2.8 cm (range 0.3 to 5.7) and had risen to 6.7 cm/year (range 2.8 to 12.4) after one year of treatment. Four patients entered puberty during the first year of treatment. No adverse side effects were observed. Further studies on greater number of patients and follow-up into adult life are needed in order to establish the efficacy of hGH therapy.
六名患有幼年特发性关节炎（JCA）的儿童和一名患有系统性红斑狼疮（SLE）的儿童，年龄在11.7至17.1岁之间，因生长迟缓接受了六个月至三年的人生长激素（hGH）治疗。他们的身高标准差分数在-2.4至-6.4之间。所有人平均已接受皮质类固醇治疗8.4年。在hGH治疗开始时，泼尼松龙的剂量较低（平均1.25毫克/天或2.75毫克/隔日）。hGH的每日剂量为0.07至0.2国际单位/千克体重/天。除一名患者外，所有患者在第一年的生长速度均有所增加。治疗前的平均生长速度为2.8厘米（范围为0.3至5.7），治疗一年后已升至6.7厘米/年（范围为2.8至12.4）。四名患者在治疗的第一年进入青春期。未观察到不良副作用。为了确定hGH治疗的疗效，需要对更多患者进行进一步研究并随访至成年期。
